Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
FLUTAMIDE
Merck Sharp & Dohme Ireland (Human Health) Limited
L02BB01
FLUTAMIDE
250 Milligram
Tablets
Product subject to prescription which may not be renewed (A)
Anti-androgens
Authorised
2010-12-10
C2102157 & C2128022 PACKAGE LEAFLET: INFORMATION FOR THE USER DROGENIL 250MG TABLETS FLUTAMIDE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any the side effects, talk to your doctor or pharmacist this includes any side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET: 1. What Drogenil is and what it is used for 2. What you need to know before you take Drogenil 250mg Tablets 3. How to take Drogenil 250mg Tablets 4. Possible side effects 5. How to store Drogenil 250mg Tablets 6. Contents of the pack and other information 1. WHAT DROGENIL IS AND WHAT IT IS USED FOR Drogenil 250mg Tablets contain flutamide, which is a medicine called an ‘antiandrogen’. These medicines stop the effects of male sex hormones which is important in the treatment of conditions that react to male sex hormones. Drogenil 250mg Tablets is used for the treatment of certain types of prostate cancer. The prostate is a walnut shaped gland found next to the bladder. Prostate cancer leads to uncontrolled growth of the prostate. This forms a tumour and causes symptoms such as: difficulty in passing urine passing urine more frequently than usual, especially at night blood in the urine pain on passing urine Prostate cancer may also Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Drogenil 250mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains flutamide 250mg. Excipients: also includes lactose monohydrate, 222mg per tablet. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. Pale yellow round, biconvex tablets with a score on one side and the SP logo on the other. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of advanced prostatic carcinoma in which suppression of testosterone effects is indicated; as initial treatment in combination with an LHRH agonist, as adjunctive therapy in patients already receiving LHRH agonist therapy; in surgically castrated patients; in the treatment of patients who have not responded to other form of hormonal manipulation or in patients who cannot tolerate such treatment. As a component of the treatment used in the management of locally confined B2 -C2 (T2b-T4) prostatic carcinoma, Drogenil Tablets are also indicated to reduce tumour volume, to increase tumour control and to extend the disease-free interval. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Dosage : One 250mg tablet three times daily at 8 hour intervals. Route of Administration : Oral When used as an initial treatment with an LHRH agonist, a greater reduction in the incidence and severity of the LHRH agonist flare reaction may be achieved if flutamide is introduced before rather than concomitantly with the agonist. It is, therefore, recommended that flutamide one tablet three times daily should be started simultaneously or 24 or more hours prior to initiation of the LHRH agonist and continued thereafter at the same dose. In Read the complete document